Breaking News
Sort by:
Date
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Cue Health Confirms COVID-19 Tests Can Detect Omicron Variant
Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it has completed an analysis […]
Helix and Cue Health Collaborate to Provide Individuals with Access to their COVID-19 Variant Sequencing Information
Helix, a leading genomics company that provides nationwide viral surveillance of respiratory disease, and Cue […]
Cue Health Announces Completion of $235 Million Private Financing to Accelerate Growth
Cue Health Inc. (“Cue Health” or “Cue”), a health technology company, today announced the closing […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more